コンテンツへスキップ
MediciNova, Inc.
  Message from CEO
  Our Mission
  Company Profile
  Management Team
  History
  Ongoing Clinical Studies
    About MN-166 (Ibudilast)
    ALS
    Oncology / Glioblastoma
    DCM
    CIPN
    ARDS / Lung Injury
    About MN-001(Tipelukast)
    NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  Press Release
  Event
  Media Archive
  Annual Report
  SEC filing
  Stock Quote -TSE
  Stock Quote -Nasdaq
  Historical Price Lookup
  Investment Calculator
  Analyst Coverage
  Corporate Governance
  Information Request
  Corporate Presentation & Resarch Reports
    Progressive Multiple Sclerosis (Progressive MS)
    Amyotrophic Lateral Sclerosis (ALS)
    Oncology / Glioblastoma
    Substance Dependence and Addiction
    MN-166 (ibudilast) News Articles
    MN-166 (ibudilast) Publications
  MN-001 Presentation
  Contact Us
Japanese site
  • About Us
    • Message from CEO
    • Our Mission
    • Company Profile
    • Management Team
    • History
  • Clinical Development
    • Ongoing Clinical Trial
    • MN-166 (Ibudilast)
      • About MN-166 (Ibudilast)
      • ALS
      • Oncology / Glioblastoma
      • DCM
      • CIPN
      • ARDS / Lung Injury
    • MN-001 ( tipelukast)
      • About MN-001(Tipelukast)
      • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
  • Investor Relations
    • Press Release
    • Event
    • Media Archive
    • Annual Report
    • SEC filing
    • Stock Quote -TSE
    • Stock Quote -Nasdaq
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
    • Corporate Governance
    • Information Request
  • Presentation
    • Corporate Presentation and Equity Research Analyst Reports
    • MN-166 Presentation
      • Progressive Multiple Sclerosis (Progressive MS)
      • Amyotrophic Lateral Sclerosis (ALS)
      • Oncology / Glioblastoma
      • Substance Dependence and Addiction
      • MN-166 (ibudilast) News Articles
      • MN-166 (ibudilast) Publications
    • MN-001 Presentation
  • Contact Us

第18回 モルガン・スタンレー・グローバル・ヘルスケア・カンファレンス 2020 への参加に関するお知らせ

2020.08.04
Page Top
medicinova_en
MediciNova, Inc.

関連記事

UBS社主催「Global Healthcare Virtual Conference」への参加に関するお知らせ

M Vest社及びMaxim Group社主催「Inaugural Emerging Growth Virtual Conference」への参加に関するお知らせ

日経Nikkei SDGs Festival におけるCMO 松田和子の登壇・講演のお知らせ

第19回 Morgan Stanley Annual Global ヘルスケア・カンファレンスへの参加に関するお知らせ

日本経済新聞社・日経BP 主催「日経 NIKKEI SDGs FESTIVAL 」当社CEO 岩城、 CMO 松田の講演模様をご視聴いただける web サイトのご案内

Maxim Group社主催ファイアーサイドチャットへの参加に関するお知らせ

日本経済新聞社・日経BP主催「日経 NIKKEI SDGs FESTIVAL」への参加に関するお知らせ
Copyright © 2021 MEDICINOVA, Inc. All Rights Reserved. | Terms of Use | Privacy Policy
    • About Us
      • Message from CEO
      • Our Mission
      • Company Profile
      • Management Team
      • History
    • Clinical Development
      • Ongoing Clinical Trial
      • MN-166 (Ibudilast)
        • About MN-166 (Ibudilast)
        • ALS
        • Oncology / Glioblastoma
        • DCM
        • CIPN
        • ARDS / Lung Injury
      • MN-001 ( tipelukast)
        • About MN-001(Tipelukast)
        • NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
    • Investor Relations
      • Press Release
      • Event
      • Media Archive
      • Annual Report
      • SEC filing
      • Stock Quote -TSE
      • Stock Quote -Nasdaq
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
      • Corporate Governance
      • Information Request
    • Presentation
      • Corporate Presentation and Equity Research Analyst Reports
      • MN-166 Presentation
        • Progressive Multiple Sclerosis (Progressive MS)
        • Amyotrophic Lateral Sclerosis (ALS)
        • Oncology / Glioblastoma
        • Substance Dependence and Addiction
        • MN-166 (ibudilast) News Articles
        • MN-166 (ibudilast) Publications
      • MN-001 Presentation
    • Contact Us
  • MediciNova, Inc.